A panel of biopharmaceutical leaders convened at the Galien Forum discussed the impacts of the Inflation Reduction Act so far ...

“Fit for Growth” has included widespread layoffs. In July 2023, Biogen said it would cut another 1,000 jobs on top of the ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

“In the two years we have worked together, Mike has demonstrated strong leadership during our Fit for Growth program, and he has been an important and valued counsel for me and our team,” Biogen CEO ...

Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of ...

Biogen shares were off about 4% at $277.10 in ... immunology and rare diseases through deals and partnerships, the new CEO said, and will be looking to cut costs. “I tell people well, there ...

Biogen raised annual profit forecast and beat third-quarter profit expectations on Wednesday, as its cost-cutting measures ...

Neomorph CEO, co-founder and president Phil Chamberlain stated: "Neomorph's molecular glue degrader platform represents a ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Biogen raised its annual profit forecast and exceeded expectations for third-quarter profit on Wednesday, as new treatments ...